title: The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
abstract: OBJECTIVE
  To evaluate the toxicity and efficacy of oxaliplatin combined with the Nordic regimen of bolus 5-fluorouracil (5-FU) and leucovorin (LV) (Nordic-FLOX) as adjuvant treatment in stage III colon cancer patients.
  
  
  METHODS
  Fifty-three patients with resected stage III colon cancer were treated with adjuvant bolus Nordic-FLOX regimen (oxaliplatin 85 mg/m(2) on day 1, bolus 5-FU 500 mg/ m(2) and bolus LV 60 mg/m(2) days 1 and 2) every 2 weeks for 12 cycles.
  
  
  RESULTS
  The probability of disease-free survival (DFS) at a median follow-up time of 29 months was 72%. Relapse was seen in 13 (24.5%) patients. The probability of 3-year overall survival (OS) at 36 months was 85%. Grade IV neutropenia was noticed in 15.1% of the patients, grade III-IV neurotoxicity was not encountered, while grade II neurotoxicity was 17%. Gastrointestinal toxicity (mild diarrhea) was seen in 11.3% of the patients.
  
  
  CONCLUSIONS
  Adjuvant treatment of stage III colon cancer with the Nordic-FLOX regimen can be an alternative regimen to infusional and other bolus regimens due to its easy administration, lower toxicity, and similar efficacy.
authors.affiliation: Izmir Ataturk Training and Research Hospital, Department of Medical Oncology, Turkey. demir.lutfiye77@gmail.com
authors.forename: L
authors.initials: L
authors.lastname: Demir
authors.forename: I
authors.initials: I
authors.lastname: Somali
authors.forename: M
authors.initials: M
authors.lastname: Oktay Tarhan
authors.forename: C
authors.initials: C
authors.lastname: Erten
authors.forename: H
authors.initials: H
authors.lastname: Ellidokuz
authors.forename: A
authors.initials: A
authors.lastname: Can
authors.forename: A
authors.initials: A
authors.lastname: Dirican
authors.forename: I
authors.initials: I
authors.lastname: Vedat Bayoglu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil